Generic drug for losartan
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Generic Drug for Losartan: Pharmacokinetics, Utilization, and Quality
Pharmacokinetics and Bioequivalence of Generic Losartan
Losartan, a nonpeptide angiotensin II receptor antagonist, is widely used as an antihypertensive agent. A study conducted on healthy Chinese male volunteers compared the pharmacokinetic parameters and relative bioavailability of a new generic losartan potassium 50-mg tablet with a branded 50-mg tablet. The study found that the generic formulation met the regulatory criteria for bioequivalence, with the 90% confidence intervals for the ratios of C_max and AUC falling within the acceptable ranges. Both formulations were well tolerated, with no serious adverse events reported.
Utilization of Generic Losartan Across Europe
The introduction of generic losartan has led to various initiatives across Europe aimed at enhancing its utilization to realize potential healthcare savings. Strategies ranged from 100% co-payment for single-sourced ARBs in Denmark to no specific measures in other countries. The study found that delisting single-sourced ARBs significantly increased losartan utilization, with Denmark achieving over 90% utilization of losartan among all ARBs by the study's end. However, in countries with no specific demand-side measures, losartan utilization actually fell. This highlights the need for multiple demand-side measures to change prescribing habits and fully realize savings from generics.
Quality Assessment of Generic Losartan
A study comparing the pharmaceutical quality of four generic losartan potassium formulations with the brand-name product Cozaar® found that three of the four generic products had a lower content of the active ingredient, ranging from 86.4% to 93.8%, which is below the acceptable threshold of 95%. While no organic impurities were detected, and elemental impurities were within acceptable limits, the lower active ingredient content in the majority of the generic products could have clinical consequences during long-term therapy.
Comparative Effectiveness and Cost-Effectiveness
A systematic review and meta-analysis compared the clinical and cost-effectiveness of candesartan and losartan in managing hypertension and heart failure. The study found that candesartan slightly reduced blood pressure more than losartan. However, this difference was not deemed cost-effective given the current acquisition costs and NHS affordability thresholds. The study recommended using generic losartan as the ARB of choice, which could save the UK NHS approximately £200 million per annum in drug costs.
Conclusion
The research indicates that generic losartan is bioequivalent to its branded counterpart and can be a cost-effective alternative for managing hypertension and heart failure. However, the quality of some generic formulations may vary, necessitating stringent quality control measures. Additionally, effective demand-side strategies are crucial to enhance the utilization of generic losartan and achieve significant healthcare savings.
Sources and full results
Most relevant research papers on this topic